英格兰1+1与2+1 PCV13婴儿免疫规划下侵袭性肺炎球菌疾病儿童特征比较
该研究比较了英格兰1+1与2+1 PCV13免疫规划下0-3岁儿童侵袭性肺炎球菌疾病(IPD)的发病率、疾病特征和结局。结果显示1+1规划组与2+1规划组的总体IPD发病率、PCV13型IPD发病率及肺炎球菌脑膜炎发病率均无显著差异,合并症、临床表现和病死率也相似。结论认为1+1规划持续提供直接和间接保护。
要点
- PCV13型IPD和肺炎球菌脑膜炎发病率在两种规划间也无显著差异。
- 合并症患病率、临床表现和病死率在两种规划间相似。
核心结论
- 1+1 PCV13规划在3年后持续提供针对PCV13型IPD的直接和间接保护,与2+1规划相比总体IPD发病率、血清型分布、临床表现或病死率无显著变化。
主要发现
- 合并症患病率、临床表现和病死率在两组间相似。
- 未接种疫苗的<2月龄婴儿和5-11月龄接受1或2剂PCV13 priming dose的婴儿病例百分比在两组间相似。
关键数值与推荐
- IPD定义为从无菌部位鉴定出肺炎链球菌。
临床怎么用
- 儿科医生可参考此研究结果,了解1+1 PCV13规划在儿童中维持与2+1规划相似的IPD保护效果。
- 需持续监测以评估1+1规划的长期直接和间接人群保护效果。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: On Jan 1, 2020, the UK transitioned from a 2+1 to a 1+1 national infant immunisation schedule with the 13-valent pneumococcal conjugate vaccine (PCV13). We assessed whether the 1+1 PCV13 schedule had any impact on incidence, disease characteristics, or outcomes after invasive pneumococcal disease (IPD) in eligible children aged 0-3 years. METHODS: The UK Health Security Agency conducts IPD surveillance and serotyping of invasive pneumococcal isolates via whole-genome sequencing in England. IPD was defined as identification of Streptococcus pneumoniae in a sterile site. We compared IPD incidence, demographics, clinical presentation, comorbidity prevalence, serotype distribution, and case-fatality rates (CFRs) in children from a single birth cohort eligible for the 1+1 schedule (born between Jan 1, 2020, and Dec 31, 2022) who developed IPD in the 2022-23 financial year (April to March) with children from three equivalent historical birth cohorts (born between Jan 1, 2015, and Dec 31, 2019) eligible for the 2+1 schedule who developed IPD during three respective pre-pandemic financial years: 2017-18, 2018-19, and 2019-20. FINDINGS: There were a total of 702 IPD episodes in 697 children, including 158 (incidence 8·99 per 100 000 person-years) in the single 1+1 birth cohort and 544 (incidence 9·39 per 100 000 person-years) in the 2+1 birth cohorts, with no significant difference in the incidence of overall IPD (incidence rate ratio 0·96, 95% CI 0·80-1·14, p=0·63), PCV13-type IPD (1·21, 0·71-2·00, p=0·45), or pneumococcal meningitis (0·97, 0·66-1·40, p=0·88). Comorbidity prevalence, clinical presentation, and CFRs were also similar between the two cohorts, as was the percentage of cases in infants too young to be vaccinated (<2 months old) and infants aged 5-11 months who received one or two PCV13 priming doses, in the 1+1 and 2+1 cohorts respectively. INTERPRETATION: After 3 years, the 1+1 schedule continues to provide direct and indirect protection against PCV13-type IPD in children, with no significant change in overall IPD incidence, serotype distribution, clinical presentation, or CFRs in children eligible for the 1+1 compared with the 2+1 schedule. Ongoing surveillance will be important to assess longer-term direct and indirect population protection. FUNDING: None.
引用
- Abdullahi F, Bertran M, D'Aeth JC, et al. Characteristics of children with invasive pneumococcal disease eligible for the 1+1 compared with the 2+1 PCV13 infant immunisation schedule in England: a prospective national observational surveillance study. Lancet Child Adolesc Health. 2024. PMID: 39332425. doi:10.1016/S2352-4642(24)00193-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。